3 news items
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
is leveraging its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company's goal
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company's goal
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
GLYC
13 Mar 24
. The Company's goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD
- Prev
- 1
- Next